In patients with acute myeloid leukemia (AML), AML1/ETO, a common AML-associated fusion protein, reduces miR-223 expression by recruiting a chromatin remodeling enzyme to the pre-miR-223 promoter binding site to silence heterochromatin of miR-223 (15). This evidence concerns the gene RUNX1T1 and acute myeloid leukemia.